Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., Board, T., Kay, P., Wroblewski, B. M., ... Global Infection Orthopaedic Management Collaboration (2018). One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies. European Journal of Epidemiology, 33(10), 933-946. https://doi.org/10.1007/s10654-018-0377-9
One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies

Setor K. Kunutsor1,2 · Michael R. Whitehouse1,2 · Ashley W. Blom1,2 · Tim Board3 · Peter Kay3 · B. Mike Wroblewski3 · Valérie Zeller4 · Suz-Yuan Chen5 · Pang-Hsin Hsieh5 · Bassam A. Masri6 · Amir Herman6 · Jean-Yves Jenny7 · Ran Schwarzkopf8 · John-Paul Whittaker9 · Ben Burston9 · Ronald Huang10 · Camilo Restrepo10 · Javad Parvizi10 · Sergio Rudelli11,12 · Emerson Honda11,12 · David E. Uip11,12 · Guillerm Bori13 · Ernesto Muñoz-Mahamud13 · Elizabeth Darley14 · Alba Ribera15 · Elena Canás16 · Javier Cabo16 · José Cordero-Ampuero17 · Maria Luisa Sorlí Redó18 · Simon Strange1 · Erik Lenguerrand1 · Rachael Gooberman-Hill1 · Jason Webb19 · Alasdair MacGowan14 · Paul Dieppe20 · Matthew Wilson21 · Andrew D. Beswick1 · The Global Infection Orthopaedic Management Collaboration

Received: 29 December 2017 / Accepted: 5 March 2018 © The Author(s) 2018

Abstract

One-stage and two-stage revision strategies are the two main options for treating established chronic peri-prosthetic joint infection (PJI) of the hip; however, there is uncertainty regarding which is the best treatment option. We aimed to compare the risk of re-infection between the two revision strategies using pooled individual participant data (IPD). Observational cohort studies with PJI of the hip treated exclusively by one- or two-stage revision and reporting re-infection outcomes were retrieved by searching MEDLINE, EMBASE, Web of Science, The Cochrane Library, and the WHO International Clinical Trials Registry Platform; as well as email contact with investigators. We analysed IPD of 1856 participants with PJI of the hip from 44 cohorts across four continents. The primary outcome was re-infection (recurrence of infection by the same organism(s) and/or re-infection with a new organism(s)). Hazard ratios (HRs) for re-infection were calculated using Cox proportional frailty hazards models. After a median follow-up of 3.7 years, 222 re-infections were recorded. Re-infection rates per 1000 person-years of follow-up were 16.8 (95% CI 13.6–20.7) and 32.3 (95% CI 27.3–38.3) for one-stage and two-stage strategies respectively. The age- and sex-adjusted HR of re-infection for two-stage revision was 1.70 (0.58–5.00) when compared with one-stage revision. The association remained consistently absent after further adjustment for potential confounders. The HRs did not vary importantly in clinically relevant subgroups. Analysis of pooled individual patient data suggest that a one-stage revision strategy may be as effective as a two-stage revision strategy in treating PJI of the hip.

Keywords Prosthesis related infection · Total hip replacement · Reoperation · Revision · Re-infection · One-stage · Two-stage · Meta-analysis

Introduction

Hip replacement is one of the most common surgical procedures. In the UK, over 95,000 primary procedures were performed in 2015 [1, 2]. In 2010, it was estimated that 2.5 million Americans were living with a hip replacement [3]. Peri-prosthetic joint infection (PJI) is a serious adverse event affecting approximately one percent of patients with a primary hip joint replacement [4] PJI has a major negative effect on patients’ quality of life [5–7],
and to avoid the need for excision arthroplasty or amputation, patients and their treating surgeons face complex and protracted treatments.

In 1985, Fitzgerald and Jones described a series of two-stage revisions for the treatment of infected hip implants [8]. With this two-stage strategy, the artificial hip joint is removed and replacement delayed for several months until clear evidence of infection eradication is obtained. An alternative one-stage revision procedure was in use from 1976 at the Endo-Klinik in Hamburg with the implant removed and replaced in one operation [9]; however the two-stage strategy has traditionally been considered the gold standard for PJI treatment [10].

Given the absence of robust evidence from a carefully designed RCT, the effectiveness of the two strategies have been compared using aggregate data from case series [11–13]. In the most recent review of 98 studies, we reported 2-year re-infection rates of about 8% following both one- or two-stage surgical revision for PJI of the hip [14]. Our findings also showed that re-infection outcomes were generally consistent for the revision strategies across important patient characteristics and surgical factors. Some features of our review limited the generalisability of the findings. First, a detailed assessment of the definition of re-infection could not be undertaken as this was not clearly reported in the majority of studies. Second, our aim was to include studies with at least 2 years of follow-up following revision surgery, but this information was not always available.

In the absence of robust evidence from a carefully designed RCT, access to individual level data from published studies could address the existing uncertainties and enable: (1) a consistent approach to the definition of outcomes; (2) a common approach across studies to statistical analyses; and (3) improved generalisability through inclusion of patients from key prospective studies worldwide.

In this context, we aimed to: (1) compare baseline and clinical characteristics of patients undergoing one-stage and two-stage revision surgery following PJI of the hip; (2) compare the risk of re-infection between the two strategies; and (3) examine the risk of re-infection according to a range of clinically relevant characteristics. To achieve our aims, we established the Global Infection Orthopaedic Management (INFORM) collaboration. This international consortium has allowed central collation and harmonisation of individual participant data (IPD) on 1856 patients from 44 cohorts based in 13 different countries across 4 continents.

**Methods**

**Data sources and search strategy**

We conducted this systematic review and IPD pooled analysis using a predefined protocol registered in the PROSPERO International prospective register of systematic reviews (CRD42015016664) [15], and in accordance with methods recommended by the IPD Meta-analysis Methods Group of the Cochrane Collaboration [16], guidance of Riley and colleagues [17], and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participants Data (PRISMA-IPD) guidelines [18] (see Appendix Supplement 1). We sought IPD from studies identified through systematic searches of MEDLINE, EMBASE, Web of Science, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and the WHO International Clinical Trials Registry Platform from March 2011 (date of our search for the previous review [13]) to February 2015 and subsequently updated to August 2016. The computer-based searches combined free text and medical subject headings and combination of key words related to hip replacement, infection, and revision with focus on one- and two-stage surgeries. There were no restrictions on language. Studies were also identified from reference lists of all retrieved articles and other relevant publications, including reviews and meta-analyses, and discussions with investigators of unpublished studies. Further details on the search strategy are presented in Appendix Supplement 2. No separate ethical approval was required for the conduct of this study, as any necessary ethical approval was obtained for each of the individual studies contributing data to this pooled analysis.

**Eligibility criteria**

Cohort studies were eligible if they met the following inclusion criteria: (1) generally unselected patients with PJI of the hip (i.e., patients’ representative of the general patient population); (2) patients treated exclusively by one-stage or two-stage revision; (3) and patients with at least 2 years of follow-up for re-infection outcomes. Peri-prosthetic joint infection was mainly diagnosed on the basis of both the presence of clinical symptoms and the results of microbiological culture from joint aspiration before surgery and/or during surgery. Majority of studies defined PJI based on diagnostic criteria proposed by the Musculoskeletal Infection Society: positive joint fluid cultures, joint fluid cell count and differentials, inflammatory markers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), presence of a sinus tract, gross
purulence observed at the time of surgery, and a positive histological exam for acute inflammation in tissues obtained during surgery. Studies that reported case series of methods in selected groups of patients (such as subsamples of patients who received revision in one- or two-stages or patients with a specific infection such as fungal infections) were excluded from the review.

**Global Infection Orthopaedic Management (INFORM) collaboration**

Details of the establishment of the Global INFORM collaboration have been reported previously in the published protocol [15]. Briefly, investigators of eligible studies identified by the literature search strategy and well-known investigators in the field, were contacted by email or letter, provided with a summary of the study protocol, and invited to join the collaboration if they had the relevant data available. Investigators expressing interest to collaborate in this effort were then provided with full details of the study protocol.

**Data collection**

Investigators were provided with a list of relevant study variables that could be used in the analyses (Appendix Supplement 3). Data from each study were obtained using a standardised spreadsheet, and data dictionaries were also requested. Details of contributing cohorts are presented in Appendix Supplement 4. The raw data were examined and inconsistencies or irregularities were clarified with the investigators. Individual level data collected was coded and entered into a single database. Additional studies were included where useable data was tabulated in published articles.

**Outcome**

The primary outcome variable was clinically diagnosed re-infection, i.e. recurrence of infection by the same organism(s) and/or re-infection with a new organism(s). Patients contributed only the first re-infection recorded after revision during follow-up. Outcomes were censored if a patient was lost to follow-up.

**Statistical analysis**

Descriptive statistics were used to summarise baseline characteristics according to the type of revision strategy. We reported mean, standard deviation (SD), median, and interquartile range (IQR) for continuous variables, and proportions for categorical variables. The risks of re-infection recorded during follow-up comparing the two-stage with the one-stage (reference category) strategy were assessed using Cox proportional shared frailty models [19], after confirmation of no major departure from the proportionality of hazards assumptions [20]. Because the treatment variable (i.e. revision strategy) only varied between studies/cohorts, inferences could only be made based on differences in re-infection rates between studies using either treatment strategy. A stratified Cox model was therefore not suitable in this scenario as the “treatment strategy” did not vary within studies. We employed a shared frailty model, which is an extension of the Cox proportional hazards model and provides a suitable way to introduce random effects in the model to account for unobserved heterogeneity. The random effect (the frailty) has a multiplicative effect on the hazard function of a cluster of individuals (cohort in this case). For each model, we included a frailty term at the cohort level to allow for dependence of individuals within each cohort. Survival curves comparing the one- and two-stage strategies were calculated using unadjusted Kaplan–Meier estimates and compared using the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with progressive adjustment for age, sex, comorbidities (Charlson comorbidity index [21]), previous hip surgery, and type of infecting organism (“difficult to treat versus “not difficult to treat” [22, 23]; Appendix Supplement 5). These covariates were selected on the basis of their role as potential confounders and evidence from previous research. Subgroup analyses were conducted using interaction tests to assess statistical evidence of any differences in HRs across categories of pre-specified individual level characteristics, specifically: sex, age group, previous hip surgery, and type of infecting organism. A two-sided P value less than 0.05 was considered statistically significant throughout and all analyses were conducted using Stata version 14 (StataCorp, College Station, Texas, USA).

**Results**

**Study identification and selection**

Figure 1 shows the inclusion and exclusion of studies. Our systematic literature search identified 4344 potentially relevant citations. After screening titles and abstracts, 59 articles remained for further evaluation. Following detailed assessments, 35 articles were excluded. The remaining 24 articles (based on 28 unique studies) and 61 articles (based on 70 unique studies) identified from our previous review [13], were potentially eligible for the pooled analysis. Of this number and in addition to three studies based on unpublished data, we had access to individual level data from 44 cohort studies. Overall, there were 13 one-stage
and 31 two-stage studies based in 13 countries (from North and South America, Europe, and Asia) (Appendix Supplements 4 and 6).

**Baseline and follow-up characteristics**

Summary baseline and follow-up characteristics of the 1856 patients with PJI of the hip treated by one- or two-stage revision that contributed to the analyses are shown in Table 1. The mean (SD) age of overall participants at baseline was 65 (13) years and 53% were men. A total of 884 patients received one-stage revision and 972 patients received two-stage revision. The median (interquartile range) follow up time was 4.2 (2.0–8.1) years in the one-stage group and 3.3 (2.0–5.9) years in the two-stage group. During follow-up, 88 (10.0%) participants experienced a re-infection in the one-stage group compared with 134 (13.8%) in the two-stage group. Although the proportion of men, mean BMI, proportion of patients having a previous procedure to treat infection, and median baseline Harris Hip Score (HHS) between the two treatment groups were generally similar, several baseline characteristics and follow-up data were not balanced between one- and two-stage groups. The one-stage revision group had older patients on average and had a higher proportion of patients with previous PJI and previous hip surgery (other than the index surgery) compared with their two-stage counterparts. In addition, the one-stage revision group had higher median levels of baseline blood circulating CRP and a higher proportion of patients presenting with an abscess, sinus, draining wound, or fistula before revision. In the two-stage group, a higher proportion of patients had a history of diabetes and other comorbidities compared with one-stage patients. The most common indication for the index implantation for both groups was osteoarthritis. This was followed by fractures in the one-stage group and...
| Total number of participants | 1856 | 884 | 972 |
|-----------------------------|------|-----|-----|

### Socio-demographic characteristics

| Gender | Overall | One-stage revision | Two-stage revision | P value |
|--------|---------|--------------------|--------------------|---------|
| Males, n (%) | N = 1743 | N = 864 | N = 879 | 0.922 |
| Females, n (%) | 926 (53.1) | 458 (53.0) | 468 (53.2) | |
| Age at baseline (years), mean (SD) | 65.1 (13.0) | 66.8 (12.4) | 63.4 (13.3) | < 0.001 |
| Smoking | N = 365 | N = 56 | N = 309 | 0.151 |
| Yes, n (%) | 86 (23.6) | 9 (16.1) | 77 (24.9) | |
| No, n (%) | 279 (76.4) | 47 (83.9) | 232 (75.1) | |
| History of high alcohol consumption | N = 110 | N = 0 | N = 110 | |
| Yes, n (%) | 6 (5.5) | 6 (5.5) | |
| No, n (%) | 104 (94.6) | 104 (94.6) | |

### Physical measurements

| Body mass index in kg/m², mean (SD) | N = 631 | N = 269 | N = 362 | 0.580 |

### Medical and surgical history

| History of diabetes | Overall | One-stage revision | Two-stage revision | P value |
|---------------------|---------|--------------------|--------------------|---------|
| Yes, n (%) | N = 803 | N = 282 | N = 521 | 0.028 |
| No, n (%) | 676 (83.7) | 247 (87.6) | 425 (81.6) | |
| History of hypertension | N = 340 | N = 157 | N = 183 | 0.501 |
| Yes, n (%) | 119 (35.0) | 52 (33.1) | 67 (36.6) | |
| No, n (%) | 221 (65.0) | 105 (66.9) | 116 (63.4) | |
| History of CVD | N = 403 | N = 161 | N = 242 | 0.714 |
| Yes, n (%) | 99 (24.6) | 38 (23.6) | 61 (25.2) | |
| No, n (%) | 304 (75.4) | 123 (76.4) | 181 (74.8) | |
| Comorbidity index | N = 785 | N = 282 | N = 503 | < 0.001 |
| No previously recorded disease categories, n (%) | 256 (32.6) | 45 (16.0) | 211 (42.0) | |
| One or two disease categories, n (%) | 433 (55.2) | 212 (75.2) | 221 (43.9) | |
| More than two disease categories, n (%) | 96 (12.2) | 25 (8.9) | 71 (14.1) | |
| History of previous PJI | N = 321 | N = 120 | N = 201 | < 0.001 |
| Yes, n (%) | 62 (19.3) | 47 (39.2) | 15 (7.5) | |
| No, n (%) | 259 (80.7) | 73 (60.8) | 186 (92.5) | |
| Previous hip surgery | N = 1060 | N = 809 | N = 251 | < 0.001 |
| Yes, n (%) | 825 (77.8) | 748 (92.5) | 77 (30.7) | |
| No, n (%) | 235 (22.2) | 61 (7.5) | 174 (69.3) | |
| Hip involved in index implantation | N = 1233 | N = 632 | N = 601 | 0.863 |
| Right, n (%) | 676 (54.8) | 348 (55.1) | 328 (54.6) | |
| Left, n (%) | 557 (45.2) | 284 (44.9) | 273 (45.4) | |

### Characteristics of infection before revision procedure

| Previous procedure performed to treat infection | Overall | One-stage revision | Two-stage revision | P value |
|------------------------------------------------|---------|--------------------|--------------------|---------|
| Yes, n (%) | N = 541 | N = 277 | N = 264 | 0.977 |
| No, n (%) | 137 (25.3) | 70 (25.3) | 67 (25.4) | |
| Presence of abscess, sinus, draining wound, or fistula at presentation | N = 588 | N = 278 | N = 310 | 0.035 |
| Yes, n (%) | 160 (27.2) | 87 (31.3) | 73 (23.6) | |
| No, n (%) | 428 (72.8) | 191 (68.7) | 237 (76.5) | |
osteonecrosis in the two-stage group (Fig. 2). The most common cultured microorganism responsible for a PJI after the index operation in the one-stage group was methicillin-sensitive Staphylococcus (S.) aureus (MSSA); whereas it was S. aureus or coagulase-negative staphylococci (CoNS) in the two-stage group. Compared to the one-stage group, there was a large percentage of negative cultures in the two-stage group (Fig. 3). The median times to onset of infection from index implantaion and from infection to revision surgery were longer in one-stage revision strategy.

### Table 1 (continued)

|                                | Overall       | One-stage revision | Two-stage revision | P value |
|--------------------------------|---------------|--------------------|--------------------|---------|
| Time from index implantation to infection (weeks), median (IQR) | 102.7 (36.6–299.2) | 154.3 (51.4–350.1) | 102.6 (32.6–268.5) | 0.142   |
| Time from infection to revision procedure (weeks), median (IQR) | 20.6 (8.4–51.4) | 30.0 (10.2–94.2)   | 12.9 (6.4–34.3)    | < 0.001 |

Baseline data before revision

|                                | Overall       | One-stage revision | Two-stage revision | P value |
|--------------------------------|---------------|--------------------|--------------------|---------|
| C-reactive protein (mg/l), [N] median (IQR) | [680] 18.9 (6.1–54.0) | [248] 22.5 (9.0–56.5) | [432] 17.1 (5.8–50.5) | 0.052   |
| Erythrocyte sedimentation rate (mm/h), [N] median (IQR) | [371] 47 (26–73) | [70] 41 (28–55) | [301] 51 (25–76) | 0.114   |
| Neutrophils/µl, [N] median (IQR) | [69] 4520 (2800–6000) | [23] 4800 (4100–6000) | [46] 3835 (99–5980) | 0.044   |
| WBC/µl, [N] median (IQR) | [285] 7380 (6020–9090) | [178] 7100 (5920–8580) | [107] 8030 (6630–10860) | 0.002   |
| Harris Hip Score, [N] median (IQR) | [171] 55.0 (48.0–60.0) | [12] 55.5 (43.5–63.5) | [159] 55–0 (48.0–60.0) | 0.656   |

Characteristics of revision procedure and management

|                                | Overall       | One-stage revision | Two-stage revision | P value |
|--------------------------------|---------------|--------------------|--------------------|---------|
| Type of re-implantation | N = 122 | N = 89 | N = 33 | 0.201   |
| Cemented, n (%) | 91 (74.6) | 65 (73.0) | 26 (78.8) |         |
| Cementless, n (%) | 23 (18.9) | 16 (18.0) | 7 (21.2) |         |
| Hybrid, n (%) | 8 (6.6) | 8 (9.0) | 0 (0.0) |         |
| Antibiotics in cement | N = 1092 | N = 758 | N = 334 | < 0.001 |
| Yes, n (%) | 750 (68.7) | 584 (77.0) | 166 (49.7) |         |
| No, n (%) | 342 (31.3) | 174 (23.0) | 168 (50.3) |         |
| Nature of spacer used | – | – | N = 293 |         |
| Unknown, n (%) | – | – | 2 (0.7) |         |
| Articulated, n (%) | – | – | 287 (98.0) |         |
| Static, n (%) | – | – | 4 (1.4) |         |
| Type of spacer | – | – | N = 183 |         |
| Unknown, n (%) | – | – | 1 (0.6) |         |
| Handmade, n (%) | – | – | 167 (91.3) |         |
| Commercial, n (%) | – | – | 15 (8.2) |         |
| Antibiotics in spacer | – | – | N = 183 |         |
| Yes, n (%) | – | – | 180 (98.4) |         |
| No, n (%) | – | – | 3 (1.6) |         |
| Duration between stages (weeks), median (IQR) | – | – | 14.5 (11.0–24.0) |         |
| Duration of antibiotics use between stages (weeks), median (IQR) | – | – | 24.0 (4.5–24.0) |         |

After revision (follow-up)

|                                | Overall       | One-stage revision | Two-stage revision | P value |
|--------------------------------|---------------|--------------------|--------------------|---------|
| Duration of antibiotic use after revision surgery (weeks), median (IQR) | 12.1 (6.1–12.6) | 12.6 (12.0–12.6) | 1.3 (0.5–5.5) | < 0.001 |
| Duration of follow-up (years), median (IQR) | 3.7 (2.0–6.9) | 4.2 (2.0–8.1) | 3.3 (2.0–5.9) | < 0.001 |
| Harris Hip Score at follow up, median (IQR) | 86.0 (73.0–93.0) | 80.0 (52.0–90.0) | 87.0 (78.0–95.0) | 0.003   |
| Number of re-infections | 222 | 88 | 134 |         |

CVD cardiovascular disease, IQR interquartile range, MR methicillin resistant, MS methicillin sensitive, PJI periprosthetic joint infection, SD standard deviation, WBC white blood cells
patients compared with two-stage patients. The median duration of antibiotic use after revision was considerably longer in the one-stage group compared with the two-stage group. However, the median duration of antibiotic therapy between stages for the two-stage revision group was about twice as long as after revision surgery in the one-stage group. Thus, patients treated with two-stage revision received a longer duration of antibiotics over the entire course of treatment (median, 18.3 weeks) compared with those treated with one-stage (median, 12.6 weeks).

Revision strategy and risk of re-infection

During a median (interquartile range) follow-up of 3.7 (2.0–6.9) years, 222 re-infections were recorded. Cumulative hazard curves demonstrated a greater risk of re-infection among two-stage revision strategy participants compared with one-stage revision strategy participants ($P < 0.001$ for log-rank test; Fig. 4). Re-infection rates per 1000 person-years of follow-up across revision strategies were 16.8 (95% CI 13.6–20.7) and 32.3 (95% CI 27.3–38.3) for the one-stage and two-stage strategies respectively. Among 1038 individuals (113 re-infections) with available survival data, comparing two- with one-stage revision, the age-adjusted HR for re-infection was 1.69 (95% CI 0.58–4.98; $P = 0.338$). The corresponding HR remained consistent 1.70 (95% CI 0.58–5.00; $P = 0.332$) on adjusting for sex; and was attenuated to 1.33 (95% CI 0.48–3.69; $P = 0.583$) after further adjustment for previous hip surgery (Table 2). The associations remained absent in analyses restricted to 439 individuals (41 re-infections) with available data on comorbidities and type of infecting organism (Table 2). HRs did not vary importantly by levels or categories of pre-specified patient level
Table 2: Hazard ratios for reinfection comparing two-stage revision versus one-stage revision adjusted progressively for risk factors

| Model | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
|-------|-----------------------|---------|-----------------------|---------|
|       | 1038 participants     |         | 439 participants      |         |
|       | (113 re-infections)   |         | (41 re-infections)    |         |
|       | with available data   |         | with available data   |         |
| Model 1 | 1.69 (0.58–4.98)   | 0.338   | 1.65 (0.44–6.20)      | 0.460   |
| Model 2 | 1.70 (0.58–5.00)   | 0.332   | 1.66 (0.44–6.24)      | 0.454   |
| Model 3 | 1.33 (0.48–3.69)   | 0.583   | 1.57 (0.45–5.51)      | 0.484   |
| Model 4 | –                    | –       | 1.59 (0.39–6.55)      | 0.520   |
| Model 5 | –                    | –       | 1.71 (0.39–7.50)      | 0.479   |

Model 1: adjusted for age
Model 2: model 1 plus sex
Model 3: model 2 plus previous hip surgery other than index surgery (yes/no)
Model 4: model 3 plus Charlson comorbidity index (no previous disease/one or two disease categories/more than two disease categories)
Model 5: model 4 plus difficult to treat organism (yes/no)

| Subgroup                        | No. of participants | No. of re-infections | HR (95% CI) | P value* |
|---------------------------------|---------------------|----------------------|-------------|---------|
| **Age at survey (years)**       |                     |                      |             |         |
| ≤ 68                            | 248                 | 21                   | 1.38 (0.32, 6.02) | .956   |
| > 68                            | 247                 | 27                   | 1.33 (0.35, 5.06) |         |
| **Sex**                         |                     |                      |             |         |
| Female                          | 198                 | 18                   | 1.08 (0.27, 4.37) | .464   |
| Male                            | 297                 | 30                   | 1.70 (0.46, 6.30) |         |
| **Previous hip surgery**        |                     |                      |             |         |
| No                              | 234                 | 32                   | 2.26 (0.54, 9.41) | .125   |
| Yes                             | 261                 | 16                   | 0.60 (0.10, 3.38) |         |
| **Difficult to treat organism** |                     |                      |             |         |
| No                              | 369                 | 31                   | 1.22 (0.34, 4.42) | .530   |
| Yes                             | 126                 | 17                   | 1.81 (0.43, 7.65) |         |
| **Period of surgery**           |                     |                      |             |         |
| ≤ 2000                          | 19                  | 6                    | 1.84 (0.23, 14.98) | .341   |
| > 2000                          | 385                 | 34                   | 0.62 (0.27, 1.39) |         |
| Both periods                    | 91                  | 8                    | 1.84 (0.23, 14.98) |         |

Fig. 5: Hazard ratios for re-infection by participant level characteristics. Hazard ratios were adjusted for age, sex, previous hip surgery other than index surgery (yes/no), and difficult to treat organism (yes/no); CI confidence interval, HR hazard ratio; *P value for interaction. Analysis was limited to 495 participants (comprising 48 re-infections) with available data.
characteristics ($P$ for interaction $> 0.10$ for each) (Fig. 5). In a post hoc subgroup analysis by period of surgery, there was no statistically significant evidence of interaction.

Comment

Key findings

This large-scale study involving pooled analysis of individual level data from 44 observational cohort studies was conducted in an attempt to address the uncertainties regarding the effectiveness of one-stage and two-stage revision strategies for treating PJI of the hip, using re-infection as the outcome of interest. With the exception of average BMI, proportions of men and patients having a previous procedure to treat infection, and median baseline HHS, which were similar between the two treatment groups; there were differences in baseline and follow-up characteristics between one- and two-stage revision strategy patients. Males were slightly overrepresented in both treatment groups, a finding which was not unexpected given that male sex is an established risk factor for PJI [24, 25]. The proportions of patients with a previous hip surgery other than the index surgery as well as a previous PJI were higher in the one-stage revision strategy group compared with the two-stage group. Patients in the one-stage revision group seemed to have severe PJI at presentation compared with the two-stage group, given their higher levels of circulating CRP and higher proportion presenting with an abscess, sinus, draining wound, or fistula. These findings were unexpected, as patients with severe PJI often undergo a two-stage revision to facilitate additional antimicrobial strategies. Given the more limited opportunities for antibiotic therapy associated with it, the one-stage revision strategy has been traditionally thought to expose patients to a higher risk of re-infection by residual bacteria [26]; and it has been suggested this strategy should only be used in selected cases, such as patients with known organisms and sensitivities, non-immunocompromised patients, as well as absence of a sinus tract [27, 28]. Our results also showed that MSSA was the most commonly isolated microorganism responsible for a PJI in the one-stage revision group. Compared with one-stage revision patients, the two-stage group had a higher proportion of patients with comorbidities. Staphylococcus species were the most common causative organisms for PJI in both treatment groups, results which are consistent with the literature [23, 29, 30]. In addition, a large percentage of two-stage patients had negative cultures compared with the one-stage group, which reflects evidence that the one-stage is commonly used in patients with known organisms and sensitivities [27].

Results on the time to onset of infection from index implantation suggested that a majority of PJIs in the one-stage group were late infections (more than 24 months after surgery), while those of the two-stage group were delayed infections (3–24 months after surgery) [31]. Given that late infections are mostly acquired by haematogenous seeding [23], this might account for the severity of PJI in the one-stage revision group.

Unadjusted cumulative hazard curves suggested a higher re-infection rate for the two-stage revision strategy compared with one-stage revision; however, given the imbalance between several baseline sociodemographic and clinical characteristics, such unadjusted results are likely to be confounded. In multivariate analyses, there was no evidence of a statistically significant increased risk of re-infection, when the two-stage revision strategy was compared with the one-stage revision strategy. However, the findings suggested there might be a higher risk of re-infection in the two-stage revision group compared to the one-stage group. The statistically non-significant associations remained consistent across clinically relevant subgroups. Given that the data collected for the current analysis spanned the period 1971 through 2011 and which might constitute a potential source of confounding for our analyses, we conducted a subgroup analysis by period of surgery and there was no evidence of effect modification by period of surgery. However, there was a suggestion of a protective effect for the period beyond the year 2000; a finding which might reflect the adoption of improved surgical strategies and use of newer and more effective antimicrobial therapies in recent times compared to previous years. However, given the small samples in these subgroups for analysis, further investigation is required.

Comparison with previous work

We are unable to directly compare the current findings with previous work; because this is to our knowledge, the first pooled analysis of individual level data from observational cohort studies based in different countries that have reported re-infection outcomes following one- or two-stage surgical revision for infected hip prostheses. However, our overall results, which suggest that the one-stage revision strategy may be as effective as the two-stage revision strategy in treating infected hip prostheses, seem to concur and further extend that of previous aggregate reviews conducted on the topic. In a review including 38 one-stage and 60 two-stage revision strategy studies, we demonstrated similar re-infection rates following one- or two-stage surgical revision for infected hip prosthesis [14]. Other similar reviews have also reported findings which suggest no significant superiority of either revision strategy over the other. Leonard and colleagues in a review of nine studies comparing re-infection rates between one- and two-
stage revision strategies, reported that one-stage revision was associated with similar re-infection rates when compared with two-stage revision, and had superior functional outcomes [32]. Lange and colleagues in a meta-analysis involving 36 studies, reported results which indicated that there were three additional re-infections per 100 patients with infected hip prosthesis when a one-stage revision was performed compared to a two-stage revision; however, the risk estimates were imprecise with overlapping confidence intervals, demonstrating no clear evidence of a superior revision strategy [33].

Implications of findings

The current findings, as well as consistent findings from several previous reviews, suggest that the one-stage revision strategy may be as effective as the two-stage strategy in treating many patients with PJI of the hip. These results are very relevant and may have clinical implications for orthopaedic practice. For several decades, the two-stage revision strategy has been presumed to be more effective that the one-stage for treating PIs [23, 34]. However, in the absence of RCTs, several individual observational cohorts, as well as reviews, have consistently failed to show clear supportive evidence for the two-stage strategy being more effective compared with the one-stage strategy. Our finding of a null association is therefore not unexpected as it confirms speculations that the two revision strategies may have comparable effectiveness for treating PJI of the hip. In unadjusted analyses which employed the entire sample in the dataset, there was statistically significant evidence of an association between the two-stage strategy and higher risk of re-infection. Therefore, it is possible that our null results on multivariate analyses could be attributed to low power, especially given the imprecise estimates (wide confidence intervals). Although claimed to be a more effective revision strategy, the two-stage strategy has several drawbacks. In addition to the significant pain and functional impairment, longer hospitalisation periods, and increased risk of mortality associated with this strategy [12, 34, 35], it is known to be associated with higher healthcare costs compared to one-stage revision [36]. For example, within the UK National Health System (NHS), the cost of surgical revision of an infected hip replacement is estimated to be about £22 000 [37]. A retrospective cost analysis performed in a hospital in France estimated the average cost (excluding social expenses) of a one-stage revision for an infected total hip replacement to be €31 133, with a two-stage procedure costing 1.7 times more than the one-stage alternative [36]. Furthermore, we have shown that patients with two-stage revision also receive a longer duration of antibiotics. There has been an increase in the use of the one-stage revision strategy [38–40] after its introduction several decades ago [9]. Despite the perceived drawback of exposing patients to a higher risk of re-infection by any residual bacteria [26], and the limited opportunities for additional antibiotic therapy; the one-stage strategy has major potential advantages for patients which include the need for fewer surgical procedures, shorter hospitalisation admissions, reduced duration of antibiotic use, less time with functional limitation and uncertainty, as well as economic benefits.

As a result of increasing life expectancy, there is a growing healthcare burden due to osteoarthritis [41], which will result in a projected increase in the numbers of primary hip replacements as well as those requiring revision surgery for PJI of the hip [42, 43]. Indeed, analysis of data for England and Wales using the National Joint Registry suggest that the volume of primary and revision hip replacements will increase by 134 and 31%, respectively between 2012 and 2030 [43]. Compared with primary hip replacement procedures, the cost of revision surgery is higher; with revision for PJI being more expensive than aseptic revisions [37]. Given the high financial costs and increased burden on resources associated especially with the two-stage revision strategy, there is a need for optimisation of resources within the current economic climate. The evidence suggests that the two revision strategies have comparable effectiveness in the control of infection in patients with peri-prosthetic hip infection. Our findings also show that the one-stage strategy is an appropriate treatment strategy for patients with characteristics that had previously been thought to be inappropriate for one-stage revision, such as those with sinus tracts at time of presentation. The overall findings suggest that the one-stage strategy might be a preferable strategy for orthopaedic surgeons performing revision surgeries for PJI of the hip.

Strengths and limitations of the study

Several strengths of this study merit consideration. We have conducted the first pooled analysis of individual level data from observational cohort studies comparing re-infection rates among patients with PJI of the hip who have undergone one- or two stage revision. Although previous aggregate reviews conducted on the topic have included a larger number of studies, the current analysis is unique in the following ways: (1) compared with single-country studies, our study pooled individual level data contributed by study investigators across four continents which enhanced generalisability of the findings; (2) there was a more consistent approach to the definition of re-infection outcomes; (3) it ensured that participants with at least 2 years of follow-up were included in the analyses; (4) there was a common approach across studies to statistical analyses; and (5) analyses included adjustment for relevant
confounders which enabled reliable assessment of the treatment effects, given the biases associated with unadjusted results. Despite the novelty and strengths of the current study, there are several limitations which deserve consideration. A main limitation was that because the revision strategy only varied between cohorts, a head-to-head comparison of the two revision strategies could not be made and appropriate inferences could only be made based on differences in re-infection rates between studies using either treatment strategy. However, given the clustered nature of the survival data, we employed a shared frailty Cox proportional model to account for any unobserved heterogeneity. The majority of studies were unable to contribute all relevant clinical data, which precluded adjustment for a comprehensive panel of potential confounders, thereby introducing the possibility of residual confounding. Given the sparsity of the data contributed by different studies, multiple imputation was not considered; as it is a challenging process in such situations and is known to produce inaccurate imputations of the missing values or does not appear to preserve relationships among variables [44]. We were also unable to conduct detailed analyses by clinically relevant subgroups such as type of PJI (early vs delayed vs late), BMI, duration of antibiotic therapy, and by population (geographical region) because of the lack of data. Apart from the control of infection, maintenance of joint function is also considered as an important factor for a successful outcome following one- or two stage revision [45, 46]. We were unable to compare the two revision strategies using measures of joint function such as the Western Ontario & McMaster Universities Arthritis Index (WOMAC) Index, a validated patient-reported outcome measure of hip pain, function and stiffness widely used in joint replacement research [47]. A number of qualitative studies (including one by our group) focusing on outcomes after joint surgery, have shown that patients are more concerned with pain and joint function (patient-centred outcome measures) rather than clinical indices such as re-infection rates [5, 48]. Because we included populations representative of patients in general clinical practice, the results cannot be generalised to selected patient populations such as immunocompromised patients, culture negative patients, and those with periprosthetic fungal infections. The findings should therefore be interpreted in context of the limitations available. Ideally, to compare the effectiveness of these two revision strategies will require evidence from a carefully designed RCT. However, given the low incidence of PJI after total hip replacement, an appropriate definitive RCT with re-infection as the primary outcome may be unlikely in the short term. Lange and colleagues report that a sample size of more than 3500 infected patients would be needed to investigate the superiority of the two-stage over one-stage revision with statistical precision, using re-infection as an outcome [33]. Within our INFection ORthopaedic Management (INFORM) Programme, which is involved in developing and establishing optimum management strategies for PJIs, there is an ongoing trial to determine whether there is a difference in patient-reported outcome measures (primary outcome) between one-stage and two-stage revision surgeries for patients with PJI of the hip (INFORM; Current controlled trials ISRCTN10956306) [49]. Results from this study may help to elucidate and address differences in the effectiveness of these two revision strategies.

In conclusion, analysis of pooled individual patient data suggests that a one-stage revision strategy may be as effective as a two-stage revision strategy in treating PJI of the hip.

Acknowledgements This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research program (RP-PG-1210-12005). This study was also supported by the NIHR Biomedical Research Centre at the University Hospitals NHS Foundation Trust and the University of Bristol. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The Global INFORM Collaboration: Setor K. Kunutsor; Michael R. Whitehouse; Ashley W. Blom; (Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK and National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, UK); Tim Board; Peter Kay; B Mike Wrobleswki (Wrightington, Wigan and Leigh NHS Foundation Trust, Appleby Bridge, Wigan, Lancashire, WN6 9EP, UK); Valérie Zeller (Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe HospitalierDiaconesses-Croix Saint-Simon, 125, rue d’Avron, 75,020 Paris, France); Szu-Yuan Chen; Pang-Hsin Hsieh (Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 5 Fu-Hsing Street, Kweishan, Taoyuan 333, Taiwan); Bassam A. Masi; Amir Herman (Department of Orthopaedics, University of British Columbia, 2775 Laurel St, Vancouver BC V5Z 1M0, Canada); Jean-Yves Jenny (Centre for Orthopaedic and Hand Surgery, University Hospital, Strasbourg, 10 avenue Baumann, 67400 Illkirch, France); Ran Schwarzkopf (Division of Adult Reconstruction, Department of Orthopedics, NYU Langone Medical Center, Hospital for Joint Diseases, New York, NY, USA); John-Paul Whittaker; Ben Burston (Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust, Oswestry SY10 7AG, UK); Ronald Huang; Camilo Restrepo; Javad Parvizi (The Rothman Institute of Orthopaedics, Thomas Jefferson University Hospital, 925 Chestnut Street, 5th Floor, Philadelphia, PA 19107, USA); Sergio Rudelli; Emerson Honda; David E. Uip (Department of Orthopaedic Surgery, Santa Casa Medical School, São Paulo, Brazil and Institute of Education and Research of Sírio Libanés Hospital, São Paulo, Brazil); Guillemin Bori; Ernesto Muñoz-Mamahud (Department of Orthopaedic and Trauma Surgery, IDIBAPS. Bone and Joint Infectious Diseases Unit, Hospital Clinic of Barcelona, University of Barcelona, C/Villarroel 170, Barcelona 08036, Barcelona, Spain); Elizabeth Darley (Severn Pathology Infection Sciences, Pathology Sciences Building, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5ND, UK); Alba Ribera (Department of Infectious Diseases, IDIBELL, Barcelona, Spain).
Hospital Universitari de Bellvitge, Feixa Llarga s/n. 08907, L’Hospitalet de Llobregat, Barcelona, Spain; Elena Cañas; Javier Cabo (Department of Orthopaedic Surgery, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s/n. 08907, L’Hospitalet de Llobregat, Barcelona, Spain); José Cordero-Ampuero (Cirugía Ortopédica y Traumatología, Hospital Universitario La Princesa, Oceano Antártico 41, Tres Cantos, 28760 Madrid, Spain); Maria Luisa Serrí Redó (Parc de Salut Mar, Department of Infectious Diseases, Passeg Maritim 25-29, Passeg Maritim 25-29, E-08003 Barcelona, Spain); Simon Strange, Erik Lenguerrand, Rachael Goodberner-Hill (Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK); Jason Webb (North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK); Aladair MacGowan (Severn Pathology Infection Sciences, Pathology Sciences Building, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5ND, UK); Paul Dieppe (University of Exeter, Medical School, Exeter, EX1 2LU, UK); Matthew Wilson (Princess Elizabeth Orthopaedic Centre, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW, UK); and Andrew D. Beswick (Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK).

Author contributors All authors of the Global INFORM Collaboration contributed to design, data collection, interpretation, and re-drafting of this paper. SKK, MRW, AWB, and ADB contributed to study conception and design, data collection, analysis, interpretation, and re-drafting of this paper. SKK, MRW, AWB, and ADB drafted the study protocol and analysis plan. SKK conducted the combined statistical analysis. SKK wrote the first draft of the manuscript.

Compliance with ethical standards

Conflict of interest Bassam A. Masri reports institutional educational support from Zimmer and DePuy. Tim Board reports institutional financial support from DePuy Synthes. Elizabeth Darley reports personal fees from Hereus Medical outside the submitted work. Michael Whitehouse reports grants from National Institute of Health personal fees from Hereus Medical outside the submitted work. Elizabeth Darley reports financial support from DePuy Synthes. Elizabeth Darley reports support from Zimmer and DePuy. Tim Board reports institutional educational support from DePuy Synthes. Bassam A. Masri reports institutional educational support from DePuy Synthes. SKK declares no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. National Joint Registry for England and Wales: 13th Annual Report. http://www.njrcentre.org.uk/resources/njr-annual-report-2016/2016. Accessed 23 Dec 2017.
2. Scottish Arthroplasty Project (2016). http://www.arthro.scot.nhs.uk/docs/2016-08-09-SAP-Report.pdf?12016. Accessed 23 Dec 2017.
3. Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am. 2015;97(17):1386–97. https://doi.org/10.2106/JBJS.N.01141.
4. Huotari K, Peltola M, Jansen E. The incidence of late prosthetic joint infections: a registry-based study of 112,708 primary hip and knee replacements. Acta Orthop. 2015;86(3):321–5. https://doi.org/10.3109/17453674.2015.1035173.
5. Moore A, Blom A, Whitehouse M, Goodberner-Hill R. Deep prosthetic joint infection: a qualitative study of the impact on patients and their experiences of revision surgery. BMJ Open. 2015;5:e009495. https://doi.org/10.1136/bmjopen-2015-009495.
6. Andersson AE, Bergh I, Karlsson J, Nilsson K. Patients’ experiences of acquiring a deep surgical site infection: an interview study. Am J Infect Control. 2010;38(9):711–7.
7. Kunutsor SK, Beswick AD, Peters TJ, et al. Health care needs and support for patients undergoing treatment for prosthetic joint infection following hip or knee arthroplasty: a systematic review. PLoS ONE. 2017;12(1):e0169068. https://doi.org/10.1371/journal.pone.0169068.
8. Fitzgerald RH, Jones DR. Hip implant infection: treatment with resection arthroplasty and late total hip arthroplasty. Am J Med. 1985;78(6):225–8.
9. Buchholz H, Elson R, Engelbrecht E, Lodenkamper H, Rottger J, Siegel A. Management of deep infection of total hip replacement. J Bone Joint Surg Am. 1981;63(3):342–53.
10. Cooper HJ, Della Valle CJ. The two-stage standard in revision total hip replacement. Bone Joint J. 2013;95-B(11 Suppl A):84–7. https://doi.org/10.1302/0301-620X.95B11.32906.
11. Gallo J, Smizansky M, Radova L, Potomkova J. Comparison of therapeutic strategies for hip and knee prosthetic joint infection. Acta Chir Orthop Traumatol Cechoslov. 2009;76(4):302–9.
12. Wolf CF, Gu NY, Doctor JDN, Manner PA, Leopold SS. Comparison of one and two-stage revision of total hip arthroplasty complicated by infection: a Markov expected-utility decision analysis. J Bone Joint Surg Am. 2011;93A(7):631–9.
13. Beswick A, Elvers K, Smith A, Goodberner-Hill R, Lovering A, Blom A. What is the evidence base to guide surgical treatment of infected hip prostheses? Systematic review of longitudinal studies in unselected patients. BMC Med. 2012;10(1):18.
14. Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD, Inform Team. Re-infection outcomes following one- and two-stage surgical revision of infected hip prosthesis: a systematic review and meta-analysis. PLoS ONE. 2015;10(9):e0139166. https://doi.org/10.1371/journal.pone.0139166.
15. Kunutsor SK, Whitehouse MR, Webb J, et al. Re-infection outcomes following one- and two-stage surgical revision of infected hip prosthesis in unselected patients: protocol for a systematic review and an individual participant data meta-analysis. Syst Rev. 2015;4:58. https://doi.org/10.1186/s13643-015-0044-0.
16. Cochrane Collaboration Individual Patient Data Meta-analysis Methods Group. FAQs (Frequently Asked Questions) on IPD meta-analysis http://www.ctu.mrc.ac.uk/cochrane/ipdmg/faq.asp, http://www.ctu.mrc.ac.uk/cochrane/ipdmg/faq.asp#faq26 (2007). Accessed 15 Dec 2017.
17. Riley RD, Lambert PC, Abo-Zaied G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:521–5. https://doi.org/10.1136/bmj.c221.
18. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–65. https://doi.org/10.1001/jama.2015.3656.
19. Hougard P. Frailty models for survival data. Lifetime Data Anal. 1995;1(3):255–73.
20. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer; 2000.
One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled...
Affiliations

Setor K. Kunutsor1,2 • Michael R. Whitehouse1,2 • Ashley W. Blom1,2 • Tim Board3 • Peter Kay3 • B. Mike Wrobleski3 • Valérie Zeller4 • Szu-Yuan Chen5 • Pang-Hsin Hsieh5 • Bassam A. Masri6 • Amir Herman6 • Jean-Yves Jenny7 • Ran Schwarzkopf8 • John-Paul Whittaker9 • Ben Burston9 • Ronald Huang10 • Camilo Restrepo10 • Javad Parviz10 • Sergio Rudelli11,12 • Emerson Honda11,12 • David E. Uip11,12 • Guillem Bori13 • Ernesto Muñoz-Mahamud13 • Elizabeth Darley14 • Alba Ribera15 • Elena Canás16 • Javier Cabo16 • José Cordero-Ampuero17 • Maria Luisa Sorlí Redo18 • Simon Strange1 • Erik Lenguerrand1 • Rachael Gooberman-Hill1 • Jason Webb19 • Alasdair MacGowan14 • Paul Dieppe20 • Matthew Wilson21 • Andrew D. Beswick1 • The Global Infection Orthopaedic Management Collaboration

1 Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, University of Bristol, Bristol BS10 5NB, UK
2 National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, UK
3 Wrightington, Wigan and Leigh NHS Foundation Trust, Appley Bridge, Wigan, Lancashire WN6 9EP, UK
4 Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d’Avron, 75020 Paris, France
5 Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 5 Fu-Hsing Street, Kweishan 333, Taoyuan, Taiwan
6 Department of Orthopaedics, University of British Columbia, 2775 Laurel St, Vancouver V5Z 1M9, BC, Canada
7 Centre for Orthopaedic and Hand Surgery, University Hospital, Strasbourg, 10 Avenue Baumann, 67400 Illkirch, France
8 Division of Adult Reconstruction, Department of Orthopedics, NYU Langone Medical Center, Hospital for Joint Diseases, New York, NY, USA
9 Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust, Oswestry SY10 7AG, UK
10 The Rothman Institute of Orthopaedics, Thomas Jefferson University Hospital, 925 Chestnut Street, 5th Floor, Philadelphia, PA 19107, USA
11 Department of Orthopaedic Surgery, Santa Casa Medical School, São Paulo, Brazil
12 Institute of Education and Research of Sirio Libanês Hospital, São Paulo, Brazil
13 Bone and Joint Infectious Diseases Unit, Department of Orthopaedic and Trauma Surgery, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, C/Villarroel 170, 08036 Barcelona, Spain
14 Severn Pathology Infection Sciences, Pathology Sciences Building, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5ND, UK
15 Department of Infectious Diseases, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s/n., L’Hospitalet de Llobregat, 08907 Barcelona, Spain
16 Department of Orthopaedic Surgery, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s/n., L’Hospitalet de Llobregat, 08907 Barcelona, Spain
17 Cirugía Ortopédica y Traumatología, Hospital Universitario La Princesa, Océano Antártico 41, Tres Cantos, 28760 Madrid, Spain
18 Department of Infectious Diseases, Parc de Salut Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain
19 North Bristol NHS Trust, Southmead Hospital, Bristol BS10 5NB, UK
20 Medical School, University of Exeter, Exeter EX1 2LU, UK
21 Princess Elizabeth Orthopaedic Centre, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW, UK